

Genovis launch Innovative IgM-Specific Protease with Wide-Ranging Applications in Life Science Markets

As a leading innovator in the field of enzyme technology, Genovis today announces the launch of its cutting-edge IgM-specific protease. This highly efficient and specific enzyme holds significant potential within various life science sectors, including research, diagnostics and therapeutic applications.

The newly developed IgM-specific protease demonstrates a remarkable level of effectiveness, exhibiting exceptional specificity towards IgM antibodies, which play a critical role in the early stages of immune response. These characteristics positions the enzyme as a valuable tool for cutting-edge research and diagnostic applications, providing researchers and diagnostic professionals with enhanced precision and accuracy in their investigations.

Moreover, data strongly suggest that the prevalence of neutralizing antibodies targeting the IgM protease among the human population is very low. This finding paves the way for potential therapeutic uses of the enzyme in diverse areas, including the treatment of cancer and autoimmune diseases. The enzyme's specific targeting of IgM presents an exciting opportunity to explore novel therapeutic strategies and open new possibilities for advancing the development of innovative treatments.

"The launch of our unique IgM-specific protease, IgMBRAZOR™, represents an important milestone in our strategy to expand our unique antibody digestion platform and position Genovis as the leading company in immunoglobulin cleaving enzymes," said Fredrik Olsson, CEO of Genovis. "With its remarkable efficiency, specificity, and potential therapeutic applications, we believe this innovative enzyme will make notable contributions to research, diagnostics, and the potential treatment of various diseases."

As part of its commitment to advancing life science research and supporting the healthcare community, Genovis plans to collaborate with leading academic institutions, research organizations, and industry partners to explore the full scope of the IgM-specific protease's applications.

For more information about Genovis's IgM-specific protease, please visit:

<https://www.genovis.com/smartenzymes/antibody-digestion/igmbrazor/>

For additional information, please contact:

Fredrik Olsson, CEO, Genovis AB

T: +46 (0)70 276 46 56

E: fredrik.olsson@genovis.com

Genovis' business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company's Certified Adviser, certifiedadviser@penser.se, tel: +46 (0)8-463 83 00.